Today: 12 June 2026
Boeing Stock Faces a Make-or-Break Test as Backlog Strength Collides With Safety Fears
6 April 2026
2 mins read

Boeing Stock Faces a Make-or-Break Test as Backlog Strength Collides With Safety Fears

NEW YORK, April 6, 2026, 11:14 EDT

Latest opinions from TipRanks and The Motley Fool added fuel to the debate around Boeing stock Monday. Bulls highlighted Boeing’s hefty backlog and its defense contracts, while bears zeroed in on ongoing safety issues, the company’s mounting debt, and a price tag that doesn’t allow for many slip-ups. Shares gained roughly 1.4% as of late morning.

This split takes center stage as Boeing heads into its first-quarter report on April 22. Investors want to see if CEO Kelly Ortberg’s turnaround is translating into more reliable output and healthier cash flow. Demand isn’t the sticking point now—execution is.

Monday’s piece from The Motley Fool pointed to Boeing’s order backlog and highlighted a fresh seven-year Pentagon pact with Lockheed Martin targeting increased PAC-3 missile seeker output. On Sunday, a separate article suggested that, despite these positives, Boeing’s safety and quality issues remain a concern for investors.

TipRanks put it in market language. In a note from the period, AI models on the platform gave Boeing scores ranging from 47 to 62. The higher numbers hinged on backlog, delivery pace and outlook for generating cash. On the other hand, the lower scores reflected concerns over debt, slim margins and the risk tied to certification.

If you’re looking for ammo, Boeing’s most recent numbers seem to have something for everyone. In January, the company reported a 34% jump in revenue for 2025, landing at $89.5 billion. The backlog hit a record $682 billion, stacked with more than 6,100 commercial jets still on order. Ortberg pointed to “significant progress” for Boeing in 2025. Boeing Investors

The cash situation at Boeing looks patchy. Free cash flow hit $375 million in Q4, but for the full year, it came in negative at $1.9 billion. Debt: $54.1 billion as of year-end. In January, CFO Jay Malave projected 2024 free cash flow somewhere between $1 billion and $3 billion, though that number hinges partly on when the 777X, 737-7, and 737-10 actually get delivered.

Some improvement is showing up on Boeing’s factory lines. The company delivered 51 jets in February—the strongest February tally since 2018. Senior supply-chain executive Ihssane Mounir said in February that Boeing was spending 40% less time on supplier fixes than it did in 2024. Over at Spirit AeroSystems, defects have dropped by 60%.

Analysts are watching production discipline more closely than new orders when it comes to Boeing’s next stock move. Doug Harned at Bernstein flagged the current output of 42 MAX jets a month as sustainable for now, thanks to previously built inventory. But he cautioned that ramping up to 47 jets monthly could stretch the supply chain. Over at BNP Paribas, Matthew Akers argued the company will need to show free cash flow topping $10 billion soon to keep bullish investors on board.

The bear scenario hardly needs much imagination. Two deadly Boeing 737 MAX crashes in 2018 and 2019 killed 346 people, and then in January 2024, an Alaska Airlines 737 MAX 9 lost a door panel mid-flight, reopening safety investigations. Boeing is still stuck in the certification process for the 737-7, 737-10, and 777X, and in March, the company flagged wiring damage on roughly 25 undelivered 737s—enough to hit its first-quarter delivery numbers.

Boeing finds itself stuck in a tricky spot. The company finally outpaced Airbus on new orders in 2025—a first in years—and it’s ramping up missile work with both the Pentagon and Lockheed Martin. Still, Airbus is the main threat in the commercial arena, and now Boeing’s commercial airplane business isn’t seen turning a profit until 2027. At this point, what matters for the stock isn’t the size of the backlog; it’s about Boeing actually converting that backlog into real deliveries, real cash, and a lot fewer nasty jolts.

Stock Market Today

  • ASX Set to Rise on US-Iran Peace Hopes; Bathurst Resources Wins NZ Court Case
    June 11, 2026, 9:12 PM EDT. Australian shares are expected to rise Friday, following strong gains on Wall Street after US President Donald Trump announced the cancellation of planned strikes on Iran and the potential for a peace deal this weekend. The S&P 500 and Dow Jones rose nearly 2%, while the Nasdaq gained 2.5%. Brent crude oil slipped below $89 per barrel. Market participants await Australia's labor account report at 11:30 am Sydney time. In corporate news, Bathurst Resources (ASX:BRL) said a New Zealand High Court dismissed Talley's Group's derivative lawsuit alleging shareholder misconduct. Ebos Group's (ASX:EBO) unit Pet Care Distributors faces regulatory review over a proposed acquisition. The ASX benchmark closed down 0.2% Thursday at 8,633.20 points.

Latest articles

AI Names Drop, Oil Upends Inflation Bets, US Stocks Slip

Dow up 930 points after hours as tech lifts Nasdaq

12 June 2026
Dow soars 929.97 points for its strongest session in months as easing geopolitical risk and a rebound in tech drive ETFs higher after hours; chip stocks surge with the PHLX Semiconductor Index up 7.9%, while Adobe drops 5.44% after CFO exit despite raised forecasts.
Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

Keel Infrastructure (KEEL) shares surge after $458 million AI data center deal closes

12 June 2026
Keel Infrastructure Corp. surged 5.14% to $5.52 after closing $458 million in 1.250% convertible senior notes due 2032, with proceeds aimed at accelerating AI and high-performance computing data center projects; the notes’ initial conversion price is $7.41, about 25% above the June 4 close, while analysts’ 12-month price targets range from $3.00 to $8.00, averaging $5.52.
IBM Stock Faces April 22 Earnings Test as AI Deals Meet Wall Street Doubts
Previous Story

IBM Stock Faces April 22 Earnings Test as AI Deals Meet Wall Street Doubts

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes
Next Story

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Go toTop